Reuters
16 Jul 2026, 10:36 UTC · 1h ago
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Reuters
16 Jul 2026, 10:36 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Eli Lilly is reportedly in talks to acquire psychedelic drug developer AtaiBeckley as soon as this week. — Potential acquisition by a major pharmaceutical company typically triggers a significant premium on the target's share price.
+0.90AtaiBeckley shares rose 50% in premarket trading following the acquisition reports. — Immediate market validation and price movement reflect investor optimism regarding the deal's likelihood.
+0.40Which stocks this story touches
Eli Lilly is reportedly in talks to acquire a drug developer, suggesting strategic growth.
Continue reading
6 related stories
Top 3 movers · tap to explore
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
